Miami Cancer Institute Begins Using Novel Treatment for Mesothelioma
The Miami Cancer Institute on Thursday will begin using the innovative Tumor Treating Fields device for patients with malignant pleural mesothelioma.
It is the first new treatment approved for mesothelioma by the U.S. Food and Drug Administration in more than 15 years.
“This is actually pretty exciting for us,” Dr. Rupesh Kotecha, the radiation oncologist who will oversee the treatment protocol in Miami, told The Mesothelioma Center at Asbestos.com. “It’s another tool in our armamentarium. It’s something we can offer patients that has shown a real benefit.”
The noninvasive Tumor Treating Fields device works by ...
Source: Asbestos and Mesothelioma News - November 6, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Pemetrexed + cisplatin in NSCLC not cost effective in Thailand
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 31, 2019 Category: Drugs & Pharmacology Source Type: news
Tumor Treating Fields Showing Early Success for Mesothelioma
Dr. Giovanni Ceresoli doesn’t think Tumor Treating Fields will work for every patient with mesothelioma cancer, but he knows it will work for some.
They are in his clinic.
As the principal investigator of the multicenter clinical trial that led to approval by the U.S. Food and Drug Administration in May, Ceresoli has played a major role in the development of this latest mesothelioma treatment.
“It might be too early to say this is a major breakthrough — we need more data — but I hope it is. I know it’s something promising, very promising,” Cerosoli told The Mesothelioma Center at Asbestos.com. “I can say tha...
Source: Asbestos and Mesothelioma News - October 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Keytruda for Mesothelioma Flops in Phase III Clinical Trial
Results from a phase III clinical trial comparing Keytruda (pembrolizumab) to standard chemotherapy shows the immunotherapy drug still has a long way to go as a viable treatment option for malignant pleural mesothelioma.
Keytruda did not improve progression-free survival for mesothelioma patients who progressed after first-line chemotherapy.
The disappointing results from the PROMISE-meso study were presented at the European Society of Medical Oncology (ESMO) annual meeting last week.
It was the first randomized trial comparing progression-free survival between immunotherapy and first-line chemotherapy for mesothelioma p...
Source: Asbestos and Mesothelioma News - October 7, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT). (Source: Roche Investor Update)
Source: Roche Investor Update - September 27, 2019 Category: Pharmaceuticals Source Type: news
Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT). (Source: Roche Media News)
Source: Roche Media News - September 27, 2019 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT). (Source: Roche Media News)
Source: Roche Media News - September 12, 2019 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT). (Source: Roche Investor Update)
Source: Roche Investor Update - September 12, 2019 Category: Pharmaceuticals Source Type: news
U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta
The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly and Co's lung cancer drug Alimta. (Source: Reuters: Health)
Source: Reuters: Health - August 29, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Mesothelioma Study Explores New Treatment When Chemotherapy Fails
A clinical trial is exploring whether a novel immunotherapy/antiangiogenic combination can serve as an effective second-line treatment for pleural mesothelioma.
Early indications of the four-center, phase II clinical trial are positive.
The combination involves nivolumab (Opdivo) , a well-known immunotherapy drug, and ramucirumab (Cyramza), a therapy drug that blocks the formation of blood vessels needed for new tumor growth.
The Food and Drug Administration approved both drugs for the treatment of other cancers, but this clinical trial is the first to test them in combination for mesothelioma.
The single-arm trial began i...
Source: Asbestos and Mesothelioma News - August 26, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news
What Is the Optimal Maintenance Therapy in Advanced NSCLC?
A phase III trial found bevacizumab and pemetrexed were effective as a maintenance therapy, but researchers do not recommend it to treat non–small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Once-Promising Drug Ofev Fails in Mesothelioma Clinical Trial
The search for a cure of mesothelioma hit another roadblock recently when a once-promising immunotherapy drug, combined with standard chemotherapy, failed to slow disease progression in a phase III study.
The multicenter study covering 27 countries involved Ofev (nintedanib), a small-molecule enzyme inhibitor drug that had shown considerable potential in earlier studies.
Lancet Respiratory Medicine published the trial results, signaling another setback for the highly anticipated use of certain immunotherapy drugs to treat mesothelioma.
“Making significant improvements in systemic therapy for malignant pleural mesotheliom...
Source: Asbestos and Mesothelioma News - July 30, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Avastin Improves Quality of Life for Mesothelioma Patients
A research team from France has documented the health-related quality-of-life benefits of adding Avastin (bevacizumab) to chemotherapy for pleural mesothelioma patients, endorsing its addition to standard-of-care treatment.
The recent quality-of-life analysis was a secondary endpoint of an earlier, multicenter clinical trial in France that showed an almost three-month median survival improvement when adding Avastin.
The latest study demonstrated that adding Avastin to cisplatin and Alimta (pemetrexed) did not negatively impact quality of life — a problem with several other cancers because of the increased toxicity.
“Co...
Source: Asbestos and Mesothelioma News - July 8, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
New Compound Could Make Chemotherapy More Effective
A research team from the Duke University Medical Center and the Massachusetts Institute of Technology has uncovered a new compound with potential to make chemotherapy more effective in treating various cancers.
The small-molecule inhibitor drug — JH-RE-06 — showed an ability to better-sensitize tumors to Cisplatin, the popular chemotherapy drug most often used for mesothelioma cancer patients.
When combined with Cisplatin, the drug also showed an ability to prevent those tumor cells from becoming treatment resistant, a common problem with this rare cancer caused by asbestos exposure.
The research was done on live mice...
Source: Asbestos and Mesothelioma News - June 27, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Adding Bevacizumab Improves Overall Survival in NSCLC
Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non - small cell lung cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 18, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Journal, Source Type: news
